Download MendeleyMolecular basis for fibroblast growth factor 23 O-glycosylation by GalNAc-T3.
de Las Rivas, M., Paul Daniel, E.J., Narimatsu, Y., Companon, I., Kato, K., Hermosilla, P., Thureau, A., Ceballos-Laita, L., Coelho, H., Bernado, P., Marcelo, F., Hansen, L., Maeda, R., Lostao, A., Corzana, F., Clausen, H., Gerken, T.A., Hurtado-Guerrero, R.(2020) Nat Chem Biol 16: 351-360
- PubMed: 31932717 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1038/s41589-019-0444-x
- Primary Citation Related Structures:
6S22, 6S24 - PubMed Abstract:
Polypeptide GalNAc-transferase T3 (GalNAc-T3) regulates fibroblast growth factor 23 (FGF23) by O-glycosylating Thr178 in a furin proprotein processing motif RHT 178 R↓S. FGF23 regulates phosphate homeostasis and deficiency in GALNT3 or FGF23 results in hyperphosphatemia and familial tumoral calcinosis. We explored the molecular mechanism for GalNAc-T3 glycosylation of FGF23 using engineered cell models and biophysical studies including kinetics, molecular dynamics and X-ray crystallography of GalNAc-T3 complexed to glycopeptide substrates. GalNAc-T3 uses a lectin domain mediated mechanism to glycosylate Thr178 requiring previous glycosylation at Thr171. Notably, Thr178 is a poor substrate site with limiting glycosylation due to substrate clashes leading to destabilization of the catalytic domain flexible loop. We suggest GalNAc-T3 specificity for FGF23 and its ability to control circulating levels of intact FGF23 is achieved by FGF23 being a poor substrate. GalNAc-T3's structure further reveals the molecular bases for reported disease-causing mutations. Our findings provide an insight into how GalNAc-T isoenzymes achieve isoenzyme-specific nonredundant functions.
- BIFI, University of Zaragoza, Mariano Esquillor s/n, Campus Rio Ebro, Edificio I+D, Zaragoza, Spain.
Organizational Affiliation:
